{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:47:18Z","timestamp":1761630438174,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.jaad.2006.10.981","type":"journal-article","created":{"date-parts":[[2007,1,23]],"date-time":"2007-01-23T07:58:09Z","timestamp":1169539089000},"page":"527-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Sorafenib-induced erythema multiforme"],"prefix":"10.1016","volume":"56","author":[{"given":"Jennifer L.","family":"MacGregor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Silvers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc E.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.10.981_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.10.981_bib2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejca.2005.11.014","article-title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: is rash associated with treatment outcome?","volume":"42","author":"Strumberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2006.10.981_bib3","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2006.10.981_bib4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.10.981_bib5","unstructured":"Nexavar (sorafenib) tablets 200 mg [product information]. Bayer Pharmaceuticals, West Haven, CT. Available at: http:\/\/www.univgraph.com\/bayer\/inserts\/NexavarNAV_PI.pdf. Accessed June 29, 2006."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:05:44Z","timestamp":1759269944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206040333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0190962206040333"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.10.981","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib-induced erythema multiforme","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.10.981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}